… Japanese patients with NSCLC treated with erlotinib,9 undertaken as a post-approval
commitment in Japan … safety and efficacy of erlotinib treatment in Japanese patients with NSCLC. …

… Caucasian patient population to the corresponding Japanese patient … Japanese patient
population before the application of the regimen in clinical practice to a wide range of patients …

… Recommended therapies for advanced/metastatic non-small cell lung cancer (NSCLC) have
… health care resource use for advanced NSCLC at 5 sites in Japan. Patients and methods …

… In conclusion, the Japanese version of the LCS can be used to evaluate multiple symptoms
in Japanese patients with lung cancer as can the original English LCS. In Japan, the LCS …

… Lung cancer remains the leading cause of cancer-related … -cell lung cancer (NSCLC)
accounts for 80% of all lung cancer … of patients with NSCLC present with locally advanced lung …

… In this phase I study in Japanese patients with advanced NSCLC using the definition defined
in … This dosage of ipilimumab is being studied in two on-going phase III lung cancer studies: …

… of patients with active tuberculosis comorbid with lung cancer will greatly decrease in the future
in Japan. … improvements in lung cancer prognosis due to advances in cancer medication, …

… This subanalysis evaluated the safety and efficacy of osimertinib specifically in 63 Japanese
patients enrolled in AURA 3. The primary end‐point was progression‐free survival ( PFS ) …

… were found in ∼25% of Japanese lung cancer patients. These EGFR mutations are reported
… status in Japanese lung cancer patients, including 102 surgically treated lung cancer cases …

… patients with advanced non-small cell lung cancer (NSCLC). This study was conducted as
the Japan Nutrition and QOL survey in patients … in further understanding cancer cachexia and …